Currently, we no longer view risk as a binary battle between genes and lifestyle. Instead, they interact, reinforce, or attenuate each other. As clinicians, staying alert to that dynamic interplay is essential, and it’s where upskilling becomes not just useful, but necessary.
To understand where risk fits in, let’s first recognize the scale of the issue. In 2022, 2.3 million new cases of female breast cancer were recorded globally, with about 670,000 deaths.
Breast cancer is now the most common cancer in women in 157 countries, spanning low-, middle-, and high-income settings alike.
Around half of all breast cancers occur in women who have no specific risk factors beyond age and sex.
In terms of trends, new cases have been rising annually by 1–5% in recent years in many countries.
By 2050, projections estimate a ~30–40% increase in breast cancer incidence and an even greater increase in mortality, especially in lower-resource countries.
These numbers tell us two things:
While “breast cancer runs in families” is a compelling narrative, only a fraction truly arises from inherited mutations. Across multiple sources, 5–10% of breast cancers are estimated to be hereditary, i.e., stemming from germline gene mutations passed down generations. That implies the vast majority (90–95%) of cases arise without a clearly inherited mutation — due to spontaneous genetic changes, environment, lifestyle, or combinations thereof.
Among inherited risk genes, BRCA1 and BRCA2 are the most widely studied. Having a harmful mutation in one of these genes significantly raises lifetime breast cancer risk. Some estimates suggest more than 60% of women with a harmful BRCA1/2 change will develop breast cancer in their lives.
But BRCA is not the whole story. Many moderate-risk genes (e.g., PALB2, ATM, CHEK2) contribute to risk in smaller degree. And then there’s the concept of polygenic risk, many small gene variants, each with tiny effect sizes, collectively shaping baseline susceptibility (even in those without a classical mutation).
The prevalence of BRCA and other gene mutations differs across populations. For instance, in sporadic breast cancer studies, BRCA mutation prevalence ranges widely (e.g., ~1.8% in Spain, higher in other populations).
This variation underscores the need for regionally tailored risk models rather than blanket assumptions from one population to another. In short, genetics provides a predisposition, not a guarantee.
While genes are immutable (for now), many aspects of lifestyle lie within reach. And in population terms, these modifiable factors may affect more cancers than hereditary ones.
Some risk factors are well established:
The simplistic question “Which matters more, genes or lifestyle?” hides a more nuanced answer. The real duel is not between them, but in how they interact with each person.
In a world where risk models are becoming multidimensional, clinicians can’t rely on “textbook” one-size approaches. The ability to interpret polygenic scores, integrate lifestyle data, stratify screening more intelligently, and counsel prevention is rapidly becoming a core competence.
That’s why programs like Medvarsity’s Fellowship in Clinical Oncology (which offers mentorship, observership, and hands-on training) are so crucial. They help doctors internalize these complex concepts and apply them in real patient care—enabling them to keep pace with rapidly evolving oncology science.
Without upskilling, clinicians risk relying on outdated models that over- or under-estimate risk for their local populations.
In this landscape, Medvarsity’s Fellowship in Clinical Oncology is not just a credential; it’s a pathway to becoming a clinician who can navigate the genetics–lifestyle interplay with clarity, confidence, and compassion. Because in the fight against breast cancer, understanding risk is just the start; guiding patients toward healthier trajectories is where impact lives.
Get in touch with our experts to learn more